Table 2. Clinical data and pathological feature of significant and insignificant incidental prostate cancer.
| Significant prostate cancer(%) | Insignificant prostate cancer(%) | P | |
| Number of Cases | 12 | 22 | |
| Mean Age at RCP (Year) | 66.83±6.83 (range 54–77) | 72.14±9.43 (range 52–86) | 0.096 |
| Preoperative PSA(ng/ml) | 2.0 | 3.7 | 0.141 |
| Prostate apex involvement by prostate cancer | 4 (33.3) | 0 (0) | 0.011 |
| Prostate stroma invasion by urothelial carcinoma | 3 (25.0) | 2 (9.1) | 0.319 |
| Biochemical recurrence | 2 (15.4) | 1 (4.5) | 0.234 |
| Prostate cancer staging | |||
| pT2a | 1 (7.7) | 18 (81.8) | |
| pT2b | 5 (41.7) | 4 (18.2) | |
| pT2c | 2 (15.4) | 0 (0) | |
| pT3a | 3 (25.0) | 0 (0) | |
| pT3b | 1(7.7) | 0 (0) | |
| Gleason Score | |||
| 3 | 0 (0) | 1 (4.5) | |
| 4 | 0 (0) | 4 (18.2) | |
| 5 | 0 (0) | 4 (18.2) | |
| 6 | 5 (41.7) | 13 (59.1) | |
| 7 | 5 (41.7) | 0 (0) | |
| 8 | 1 (7.7) | 0 (0) | |
| 9 | 1 (7.7) | 0 (0) | |
| Bladder cancer staging | |||
| pT1 | 1(8.3) | 2(9.1) | 0.614 |
| pT2 | 5(41.7) | 13(59.1) | |
| pT3 | 3(25.0) | 5(22.7) | |
| pT4 | 3(25.0) | 2(9.1) | |
| Bladder cancer lymph node involvement | |||
| N0 | 10(83.3) | 18(81.8) | 0.742 |
| N1 | 2(16.7) | 3(13.6) | |
| N2 | 0(0) | 1(4.5) | |